文献速递造血干细胞移植与细胞治疗

选择性JAK1抑制剂乌帕替尼治疗激素难治性慢性移植物抗宿主病:一项多中心真实世界研究

Upadacitinib, a selective JAK1 inhibitor, for the treatment of steroid refractory chronic graft-versus-host disease: A multicentre real-world study.
PubMed 文献 · Br J Haematol · 2025-06-16

该多中心真实世界研究纳入中国三家医院的32例激素难治性慢性移植物抗宿主病患者,评估乌帕替尼治疗的临床结局。24周总缓解率为81.3%,任何时间总缓解率为84.4%,皮肤特异性缓解率更高,感染和血液学毒性发生率分别为18.75%和6.25%。作者认为乌帕替尼可能为激素难治性慢性移植物抗宿主病的有效且安全的治疗选择。

要点

  • 24周总缓解率81.3%,其中完全缓解率21.9%、部分缓解率59.4%。
  • 任何时间总缓解率84.4%,完全缓解率21.9%、部分缓解率62.5%。
  • 感染发生率18.75%,血液学毒性发生率6.25%,2例(6.25%)发生III级不良事件。

核心结论

  • 作者认为乌帕替尼可能为激素难治性慢性移植物抗宿主病的有效且安全的治疗选择。

研究设计与样本

  • 该研究为多中心真实世界研究,纳入来自中国三家医院的32例接受乌帕替尼治疗的激素难治性慢性移植物抗宿主病患者。

主要发现

  • 24周总缓解率为81.3%,其中完全缓解率21.9%、部分缓解率59.4%。
  • 任何时间总缓解率为84.4%,其中完全缓解率21.9%、部分缓解率62.5%。
  • 24周皮肤特异性总缓解率为84.4%,其中完全缓解率40.6%、部分缓解率43.8%。
  • 任何时间皮肤特异性总缓解率为87.6%,其中完全缓解率43.8%、部分缓解率43.8%。
  • 感染发生率为18.75%,血液学毒性发生率为6.25%,2例(6.25%)发生III级不良事件;1例死于复发,无非复发死亡。

关键数值与推荐

  • 乌帕替尼治疗后1年总生存概率、无失败生存概率和无病生存概率分别为96.6%、64.9%和83.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains an important cause of morbidity and mortality after allo-HSCT. Upadacitinib is a selective JAK1 inhibitor. This study investigated the clinical outcomes of upadacitinib in patients with steroid refractory (SR) chronic graft-versus-host disease (cGVHD). Thirty-two patients with steroid refractory cGVHD (SR-cGVHD) who received upadacitinib treatment were enrolled from three hospitals in China. The overall response rates (ORRs) at 24 weeks and at any time were 81.3% (complete response [CR] rate: 21.9%; partial response [PR] rate: 59.4%) and 84.4% (CR rate: 21.9%; PR rate: 62.5%) respectively. In particular, the cutaneous-specific ORRs at week 24 and at any time were 84.4% (CR rate: 40.6%, PR rate: 43.8%) and 87.6% (CR rate: 43.8%; PR rate: 43.8%) respectively. The rates of infection and haematological toxicity were 18.75% and 6.25%, and two patients (6.25%) experienced grade III adverse events after upadacitinib treatment. One patient died from relapse, and no patient died from non-relapse mortality. The 1-year probabilities of overall survival, failure-free survival and disease-free survival after upadacitinib were 96.6%, 64.9% and 83.1% respectively. In summary, upadacitinib may be an effective and safe treatment for SR-cGVHD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Niu L, Hu M, Xia Y, et al. Upadacitinib, a selective JAK1 inhibitor, for the treatment of steroid refractory chronic graft-versus-host disease: A multicentre real-world study. Br J Haematol. 2025. PMID: 40518809. doi:10.1111/bjh.20183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。